Clariane stock abandons 4% and deepens its decline to 16% over one week
The group of specialized nursing homes and home care services extends its downward slide and ranks among the most penalized securities in the broad index, in a Paris market itself oriented downward. The stock moves against the grain of rates, as tension on French debt persists and the session remains difficult for the healthcare sector.
A stock below its three moving averages, 16% below the MA20
The Clariane stock declines 4.09% to €3.15 in trading, while the SBF 120 falls 0.81%. Among the strongest declines in the index, the stock is now down nearly 16% over one week and more than 20% over one month. The price is below its MA20 (gap of -16.55%, or €3.77), but also below its MA50 at €3.91 and its MA200 at €3.93, which places all three moving averages clearly above the quotation. The support level of €3.28, which corresponded to the previous day's close, does not hold, and the RSI at 27 signals an oversold configuration.
French debt at 4.83% and refinancing completed in September
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The yield on the 10-year OAT was 4.83% on October 7, or 1.34 percentage points above the German Bund, and has gained 64 basis points in one month. Such a rate level weighs on groups with high debt levels, and the renewable credit line of €700 million due in 2031 signed on September 22 falls within this financing framework. During the publication of H1 2026 results (July 29, 2026), the group had reported the refinancing of €1,063 million in debt and targeted an improvement in EBITDA margin of 100 to 150 basis points by the end of 2026. Within the SBF 120, Emeis, another player in the sector, is also down 6.34% this morning.
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2 699 millions d'euros
Quarterly revenue: 2 699 millions d'euros
Revenue growth: 1,6 %
EBITDA: 524 millions d'euros
EBITDA margin: 10,4 %
Net income: -47,5 millions d'euros
Free cash flow: 20 millions d'euros
3 020 millions d'euros
Guidance from the release
Le Groupe s'appuiera principalement sur la poursuite de l'amélioration de la performance opérationnelle et le maintien d'une stricte discipline d'investissements
Risks mentioned
Environnement géopolitique complexe affectant les opérations de refinancement
Exposition aux épisodes climatiques frappant durement certains territoires en Europe
Pression inflationniste continue sur les coûts opérationnels malgré les gains tarifaires
Opportunities identified
Amélioration de la marge EBITDA de 100-150 points de base d'ici fin 2026
Croissance des volumes d'activité portée par l'augmentation progressive des taux d'occupation
Refinancement réussi de €1 063m renforçant la flexibilité financière et réduisant le coût de la dette
Outlook / guidance
Expected revenue: 5 522 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
